Proactiveinvestors USA & Canada Amryt Pharma PLC https://www.proactiveinvestors.com Proactiveinvestors USA & Canada Amryt Pharma PLC RSS feed en Tue, 21 May 2019 06:10:08 -0400 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Euronext Growth Dublin Suspension Notice ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190521073001_14081406/ Tue, 21 May 2019 02:30:01 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190521073001_14081406/ <![CDATA[RNS press release - Recommended Acquisition of Aegerion ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190521070021_14080979/ Tue, 21 May 2019 02:00:21 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190521070021_14080979/ <![CDATA[RNS press release - Preliminary Results and Q1 Trading Update ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190417070003_14043819/ Wed, 17 Apr 2019 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190417070003_14043819/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190412100454_14039348/ Fri, 12 Apr 2019 05:04:54 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190412100454_14039348/ <![CDATA[RNS press release - Update on AP101 EASE Phase III trial ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190228070022_13984460/ Thu, 28 Feb 2019 02:00:22 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190228070022_13984460/ <![CDATA[RNS press release - Positive results for gene therapy AP103 ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190107070004_13925013/ Mon, 07 Jan 2019 02:00:04 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190107070004_13925013/ <![CDATA[RNS press release - EASE Phase III trial interim efficacy results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20190104125617_13924515/ Fri, 04 Jan 2019 07:56:17 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20190104125617_13924515/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20181221140551_13913631/ Fri, 21 Dec 2018 09:05:51 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20181221140551_13913631/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20181221140048_13913623/ Fri, 21 Dec 2018 09:00:48 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20181221140048_13913623/ <![CDATA[RNS press release - Update on ongoing AP101 Trial ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20181219070003_13908835/ Wed, 19 Dec 2018 02:00:03 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20181219070003_13908835/ <![CDATA[RNS press release - Grant Funding from Irish Government for AP103 ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20181210113002_13897659/ Mon, 10 Dec 2018 06:30:02 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20181210113002_13897659/ <![CDATA[RNS press release - Lojuxta to be reimbursed in France ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20181017070005_13831406/ Wed, 17 Oct 2018 02:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20181017070005_13831406/ <![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180926070004_13804541/ Wed, 26 Sep 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180926070004_13804541/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180914070009_13790601/ Fri, 14 Sep 2018 02:00:09 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180914070009_13790601/ <![CDATA[RNS press release - Amryt receives IND approval from FDA for AP101 ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180910070006_13783840/ Mon, 10 Sep 2018 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180910070006_13783840/ <![CDATA[RNS press release - FDA grants Pediatric Rare Disease designation ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180802070006_13740617/ Thu, 02 Aug 2018 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180802070006_13740617/ <![CDATA[RNS press release - Trading update & significant momentum building ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180719070005_13723310/ Thu, 19 Jul 2018 02:00:05 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180719070005_13723310/ <![CDATA[RNS press release - NHS England approves funding for Lojuxta ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180709070004_13709595/ Mon, 09 Jul 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180709070004_13709595/ <![CDATA[RNS press release - Change of Registered Address ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180706070004_13707892/ Fri, 06 Jul 2018 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180706070004_13707892/ <![CDATA[RNS press release - Company name alteration for previous release ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180625081029_13691787/ Mon, 25 Jun 2018 03:10:29 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180625081029_13691787/ <![CDATA[RNS press release - Positive data of Pollinex Quattro Grass vaccine ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180625070010_13691237/ Mon, 25 Jun 2018 02:00:10 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180625070010_13691237/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180605104135_13667419/ Tue, 05 Jun 2018 05:41:35 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180605104135_13667419/ <![CDATA[RNS press release - Four Middle East Lojuxta® Distribution Agreements ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180529070016_13657122/ Tue, 29 May 2018 02:00:16 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180529070016_13657122/ <![CDATA[RNS press release - Exclusive Lojuxta® Licence Expanded ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180510070008_13635497/ Thu, 10 May 2018 02:00:08 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180510070008_13635497/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180509144830_13635002/ Wed, 09 May 2018 09:48:30 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180509144830_13635002/ <![CDATA[RNS press release - Holding(s) in Company and Lock-in agreement ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180508070013_13631814/ Tue, 08 May 2018 02:00:13 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180508070013_13631814/ <![CDATA[RNS press release - Posting of Annual Report 2017 and Notice of AGM ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180504070006_13629804/ Fri, 04 May 2018 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180504070006_13629804/ <![CDATA[RNS press release - Final Results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180417070003_13606631/ Tue, 17 Apr 2018 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180417070003_13606631/ <![CDATA[RNS press release - Trading update & Gene therapy agreement ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180315070006_13567542/ Thu, 15 Mar 2018 03:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180315070006_13567542/ <![CDATA[RNS press release - Senior Management Appointment ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180306070006_13555670/ Tue, 06 Mar 2018 02:00:06 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180306070006_13555670/ <![CDATA[RNS press release - Distribution Agreement for Lojuxta in Middle East ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180306070004_13555622/ Tue, 06 Mar 2018 02:00:04 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180306070004_13555622/ <![CDATA[RNS press release - Notice of Trading Update ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180302070005_13552104/ Fri, 02 Mar 2018 02:00:05 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180302070005_13552104/ <![CDATA[RNS press release - New Distribution Agreement Signed ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180130070002_13513676/ Tue, 30 Jan 2018 02:00:02 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180130070002_13513676/ <![CDATA[RNS press release - Senior Management Team Appointment ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180124070006_13507122/ Wed, 24 Jan 2018 02:00:06 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180124070006_13507122/ <![CDATA[RNS press release - New Distribution Agreement Signed ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180110070002_13490812/ Wed, 10 Jan 2018 02:00:02 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180110070002_13490812/ <![CDATA[RNS press release - Distribution Agreement Signed Covering Switzerland ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20180108070003_13487666/ Mon, 08 Jan 2018 02:00:03 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20180108070003_13487666/ <![CDATA[RNS press release - Senior Management Team Appointment ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171220070004_13471807/ Wed, 20 Dec 2017 02:00:04 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171220070004_13471807/ <![CDATA[RNS press release - Grant of Options & PDMR Dealings ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171201070007_13450318/ Fri, 01 Dec 2017 02:00:07 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171201070007_13450318/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171120163535_13437903/ Mon, 20 Nov 2017 11:35:35 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171120163535_13437903/ <![CDATA[RNS press release - Distribution Agreement Signed in Saudi Arabia ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171113070003_13428514/ Mon, 13 Nov 2017 02:00:03 -0500 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171113070003_13428514/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171013152928_13396691/ Fri, 13 Oct 2017 10:29:28 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171013152928_13396691/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171011070003_13392494/ Wed, 11 Oct 2017 02:00:03 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171011070003_13392494/ <![CDATA[RNS press release - Result of General Meeting & Completion of Placing ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20171009121320_13390480/ Mon, 09 Oct 2017 07:13:20 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20171009121320_13390480/ <![CDATA[RNS press release - Placing to raise EUR 15m ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20170921070004_13370170/ Thu, 21 Sep 2017 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20170921070004_13370170/ <![CDATA[RNS press release - Interim Results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20170904070004_13349961/ Mon, 04 Sep 2017 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20170904070004_13349961/ <![CDATA[RNS press release - Attendance at Rodman & Renshaw Conference ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20170831070006_13346554/ Thu, 31 Aug 2017 02:00:06 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20170831070006_13346554/ <![CDATA[RNS press release - Senior Management Appointment ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20170830070004_13344954/ Wed, 30 Aug 2017 02:00:04 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20170830070004_13344954/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.com/companies/rns/3950/LSE20170823083015_13339069/ Wed, 23 Aug 2017 03:30:15 -0400 https://www.proactiveinvestors.com/companies/rns/3950/LSE20170823083015_13339069/ <![CDATA[Media files - Orphan drug status for new compound 'great news' says Amryt Pharma PLC's COO ]]> https://www.proactiveinvestors.com/companies/stocktube/6339/orphan-drug-status-for-new-compound-great-news-says-amryt-pharma-plc-s-coo-6339.html Mon, 07 Nov 2016 09:10:00 -0500 https://www.proactiveinvestors.com/companies/stocktube/6339/orphan-drug-status-for-new-compound-great-news-says-amryt-pharma-plc-s-coo-6339.html <![CDATA[News - Amryt Pharma granted US patent for lead drug ]]> https://www.proactiveinvestors.com/companies/news/165815/amryt-pharma-granted-us-patent-for-lead-drug-165815.html Amryt Pharma has been granted a US patent for its lead drug, Episalvan, a treatment for Epidermolysis Bullosa (EB).  a rare, hereditary skin disorder.

The most serious cases lead to disfigurement and cause intense suffering. 

Children with this disorder are frequently referred to as "Butterfly Children". 

Episalvan has already shown faster healing for wounds and chronic wounds compared to standard care and Amryt (LON:AMYT)  is now preparing a phase III trial for the drug's use in EB treatment.

Europe’s medicines agency granted Episalvan a patent for the treatment of all partial thickness wounds in January.

Amryt estimates that the global EB market is worth US$1.5bn per annum.

Joe Wiley, chief executive, said he hoped the phase III trial for the use of Episalvan in EB treatment would start in the first quarter of 2017.

A meeting of the US Food and Drug Administration is planned for early in the next quarter to establish the trial’s study protocol. A clinical research organisation has been identified to conduct the phase III study.

A US application has also been made for orphan designation for AP102, a treatment for excess growth hormone condition acromegaly, with a pre-clinical study to be completed in coming weeks.

Amryt, which reversed into oil and gas group Fastnet in April, has cash of €10.7mln and posted a loss of €4.1mln in the half year to June.

]]>
Tue, 13 Sep 2016 08:44:00 -0400 https://www.proactiveinvestors.com/companies/news/165815/amryt-pharma-granted-us-patent-for-lead-drug-165815.html